MedTrace Logo

Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

NCT01378546 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2013-07-18

No results posted yet for this study

Summary

Lambert Eaton Myasthenic Syndrome (LEMS) is rare neurological disorder that results in muscle weakness and limited reflex activity. More than half of LEMS cases are associated with a malignancy, usually small cell lung cancer, and tend to progress more quickly than cases not coupled with malignant cells.

3,4diaminopyridine (3,4DAP)is a drug that has been demonstrated to be effective in treating the weakness associated with LEMS as it increases strength and improves autonomic symptoms in LEMS patients. It is not currently approved by the FDA for use in the United States. The investigators plan to use 3,4DAP to treat patients with LEMS here at the Columbia University MDA/ALS Research Center.

Conditions

  • Lambert Eaton Myasthenic Syndrome (LEMS)

Interventions

DRUG

3,4-diaminopyridine

Treatment will begin with 5mg three times a day or less.

Sponsors & Collaborators

  • Louis H. Weimer, MD

    lead OTHER

Principal Investigators

  • Louis H Weimer, MD · Columbia University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2015-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01378546 on ClinicalTrials.gov